Shares in digital imaging systems producer Agfa Gevaert climbed on Thursday after it said it had declined to engage in talks with privately-held Kanteron Systems regarding a potential takeover bid.
The company said that it had received a non-binding letter of intent from Kanteron Systems relating to a voluntary conditional leveraged takeover offer on Sept. 11, confirming information from a blog post published by Kanteron a day before.
“Agfa Healthcare business unit revenues have been stagnant in the last few years. However, a deal with Kanteron would allow Agfa to tap into our leading-edge technology,” Kanteron Systems CEO Jorge Cortellin said in the post.
Kanteron Systems is a Spanish software company active in the healthcare and biomedical IT business, helping manage imaging and genomics data for precision medicine applications.
Agfa said in a statement that its management decided not to engage in discussions with Kanteron Systems at this stage.
Contacted for further comment, company spokesman Johan Jacobs said that “at this stage, we are not convinced that it’s an interesting offer”.
Kanteron Systems was not immediately available for comment.
Agfa’s shares jumped 8.5 percent on the Brussels stock exchange, right after the announcement. At 0840 GMT, the shares were up 3.6 percent.
By Piotr Lipinski
Source: Reuters
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.
DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.
Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.
